Complete Hematologic Response

Known as: CHR 
The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable… (More)
National Institutes of Health

Related topics

Related topics

1 relation
Clinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.
Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is highly effective in multiple myeloma. We treated patients with light… (More)
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
BACKGROUND Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome… (More)
  • table 1
  • table 2
  • table 2
  • table 3
  • table 3
Is this relevant?
2009
2009
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
BACKGROUND Although many patients with chronic myeloid leukemia (CML) respond well to imatinib therapy, a significant proportion… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2009
2009
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients…
Second-generation tyrosine kinase inhibitors are effective in Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.
Long-term survival and outcome were determined for 80 patients with immunoglobulin light chain (AL) amyloidosis treated with high… (More)
  • figure 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Developing strategies to counteract imatinib resistance constitutes a challenge in chronic myelogenous leukemia (CML). Therapy… (More)
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?
Hepatitis C virus (HCV) has been associated with the development of B-cell non-Hodgkin lymphomas. We recently reported the… (More)
  • table 2
  • table 1
Is this relevant?
2005
2005
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis
Summary:Serum free light-chain (FLC) concentrations were measured by a sensitive nephelometric immunoassay in 66 patients with AL… (More)
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Twenty-eight adults with chronic myelogenous leukemia (CML) that had relapsed after allogeneic stem cell transplantation (SCT… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
1995
1995
Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- Therapy
Table. SI Units and Abbreviation Chronic myelogenous leukemia is characterized by the presence of the Philadelphia chromosome (Ph… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?